Avalyn Pharma Inc. Common Stock (AVLN) vs Teladoc Health, Inc. (TDOC)
A side-by-side comparison of Avalyn Pharma Inc. Common Stock and Teladoc Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVLN
Avalyn Pharma Inc. Common Stock
$26.29HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
TDOC
Teladoc Health, Inc.
$5.73HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — AVLN vs TDOC
growth of $100 · dividends reinvested · last 1yAVLN -8.3% (-8.3%/yr)TDOC -4.5% (-4.5%/yr)TDOC compounded faster over this window
AVLN TDOC
AVLN vs TDOC: by the numbers
- •AVLN is the larger company ($1.17B vs $1.04B market cap).
- •Both run net losses; AVLN's is the smaller (0.00% vs -7.13% net margin).
Metrics side by side
Valuation
| Metric | AVLN | TDOC |
|---|---|---|
| P/S ratio | N/A | 0.42 |
| P/B ratio | 2.93 | 0.79 |
| EV / EBITDA | N/A | 12.82 |
| FCF yield | N/A | 21.58% |
Profitability
| Metric | AVLN | TDOC |
|---|---|---|
| Gross margin | 0.00% | 73.53% |
| Operating margin | 0.00% | -6.98% |
| Net margin | 0.00% | -7.13% |
| ROE | N/A | -13.54% |
| ROIC | -67.73% | -7.32% |
Growth (annualized)
| Metric | AVLN | TDOC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.85% |
| Total return CAGR (5Y) | N/A | -45.85% |
Go deeper
Dig into the metrics
Avalyn Pharma Inc. Common Stock ROETeladoc Health ROEAvalyn Pharma Inc. Common Stock operating marginTeladoc Health operating marginAvalyn Pharma Inc. Common Stock revenue growthTeladoc Health revenue growthAvalyn Pharma Inc. Common Stock free cash flowTeladoc Health free cash flow
Avalyn Pharma Inc. Common Stock & Teladoc Health appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.